(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, the Ocular Hypertension pipeline constitutes 70+ key companies continuously working towards developing 75+ Ocular Hypertension treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

“Ocular Hypertension Pipeline Insight, 2023″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Ocular Hypertension Market.

 The Ocular Hypertension Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

To know more about the Ocular Hypertension pipeline report offerings, click here @ Ocular Hypertension pipeline analysis

 

Some of the key takeaways from the Ocular Hypertension Pipeline Report:

• Ocular Hypertension Companies across the globe are diligently working toward developing novel Ocular Hypertension treatment therapies with a considerable amount of success over the years. 
• Ocular Hypertension companies working in the treatment market are Nicox, Qlaris Bio, TheratOcular Biotek Co., Ocular Therapeutix, Whitecap Biosciences, JeniVision, Inc., AbbVie, Santen, VivaVision Biotech, ONL Therapeutics, Skye Bioscience, MediPrint Ophthalmics, Sun Pharma Advanced Research Company, Ripple Therapeutics, Peregrine Ophthalmic, Laboratorios Sophia, Whitecap Biosciences, pH Pharma, Chong Kun Dang, Laboratoires Thea are developing therapies for the Ocular Hypertension treatment 

• Emerging Ocular Hypertension therapies such as – TO-O-1001, QLS-101, NCX-470, and others are expected to have a significant impact on the Ocular Hypertension market in the coming years.
• NCX 470, is a novel nitric oxide (NO)-donating bimatoprost eye drop, currently in Phase III clinical development for the lowering of intraocular pressure (IOP) in patients with open angle glaucoma or ocular hypertension.
• QLS-101 is an investigational therapy, designed to lower intraocular pressureP) by reducing episcleral venous pressure (EVP) in individuals with glaucoma. It is currently in Phase II trial in adolescents with Sturge-Weber syndrome (SWS) who have clinical evidence of glaucoma and/or ocular hypertension (OHT) related to SWS elevated EVP in at least one eye.

 

Ocular Hypertension Overview

Ocular hypertension occurs when the pressure inside the eye exceeds the range considered normal and goes higher than 21 mm Hg. The increase in intraocular pressure (progressive with age, although may also be due to other disorders or causes) is the main risk factor for developing glaucoma and, therefore, people with ocular hypertension are more likely to suffer the disease. However, the two are different: ocular hypertension means that the intraocular pressure is high but the optic nerve is not damaged, whereas with glaucoma, the optic nerve has been damaged – and intraocular pressure might be normal or high – which can lead patients to notice a loss of visual field and even central vision in advanced stages of the disorder.

 

Get a Free Sample PDF Report to know more about Ocular Hypertension Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/ocular-hypertension-pipeline-insight

 

Emerging Ocular Hypertension Drugs Under Different Phases of Clinical Development Include:

• NCX-470: Nicox
• QLS-101: Qlaris Bio
• TO-O-1001: TheratOcular Biotek Co., Ltd.
• And many others

 

Ocular Hypertension Pipeline Therapeutics Assessment

• Ocular Hypertension Assessment by Product Type
• Ocular Hypertension By Stage and Product Type
• Ocular Hypertension Assessment by Route of Administration
• Ocular Hypertension By Stage and Route of Administration
• Ocular Hypertension Assessment by Molecule Type
• Ocular Hypertension by Stage and Molecule Type

 

DelveInsight’s Ocular Hypertension Report covers around 75+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

 

Further Ocular Hypertension product details are provided in the report. Download the Ocular Hypertension pipeline report to learn more about the emerging Ocular Hypertension therapies- https://www.delveinsight.com/sample-request/ocular-hypertension-pipeline-insight

 

Ocular Hypertension Pipeline Analysis:

The Ocular Hypertension pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Ocular Hypertension with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ocular Hypertension Treatment.
• Ocular Hypertension key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Ocular Hypertension Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Ocular Hypertension market.

 

Download Sample PDF Report to know more about Ocular Hypertension drugs and therapies- https://www.delveinsight.com/sample-request/ocular-hypertension-pipeline-insight

  

Scope of Ocular Hypertension Pipeline Drug Insight    

• Coverage: Global
• Key Ocular Hypertension Companies: Nicox, Qlaris Bio, TheratOcular Biotek Co., Ocular Therapeutix, Whitecap Biosciences, JeniVision, Inc., AbbVie, Santen, VivaVision Biotech, ONL Therapeutics, Skye Bioscience, MediPrint Ophthalmics, Sun Pharma Advanced Research Company, Ripple Therapeutics, Peregrine Ophthalmic, Laboratorios Sophia, Whitecap Biosciences, pH Pharma, Chong Kun Dang, Laboratoires Thea, and others
• Key Ocular Hypertension Therapies: TO-O-1001, QLS-101, NCX-470, and others.
• Ocular Hypertension Therapeutic Assessment: Ocular Hypertension current marketed and Ocular Hypertension emerging therapies
• Ocular Hypertension Market Dynamics: Ocular Hypertension market drivers and Ocular Hypertension market barriers 

 

Request for Sample PDF Report for Ocular Hypertension Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/ocular-hypertension-pipeline-insight

 

Table of Contents

1	Ocular Hypertension Report Introduction
2	Ocular Hypertension Executive Summary
3	Ocular Hypertension Overview
4	Ocular Hypertension- Analytical Perspective In-depth Commercial Assessment
5	Ocular Hypertension Pipeline Therapeutics
6	Ocular Hypertension Late Stage Products (Phase II/III)
7	Ocular Hypertension Mid Stage Products (Phase II)
8	Ocular Hypertension Early Stage Products (Phase I)
9	Ocular Hypertension Preclinical Stage Products
10	Ocular Hypertension Therapeutics Assessment
11	Ocular Hypertension Inactive Products
12	Company-University Collaborations (Licensing/Partnering) Analysis
13	Ocular Hypertension Key Companies
14	Ocular Hypertension Key Products
15	Ocular Hypertension Unmet Needs
16	Ocular Hypertension Market Drivers and Barriers
17	Ocular Hypertension Future Perspectives and Conclusion
18	Ocular Hypertension Analyst Views
19	Appendix
20	About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting